Cresilon makes medical devices that stop bleeding with a plant-based adhesive gel. Its main product, VETIGEL, is a fast-acting gel designed to control bleeding in veterinary patients, and Cresilon serves human trauma and surgical markets as well. The gel is applied to a wound and works to seal and promote clotting within seconds without needing manual pressure. Cresilon differentiates itself by offering a gel-based hemostat and by being among the first to target veterinary applications with a rapid, easy-to-use solution, along with direct sales and partnerships (for example, the VerticalVet Preferred Partnership) to reach clinics and hospitals. The company’s goal is to broaden the gel technology’s uses to improve wound care and save lives across veterinary, human trauma, and surgical settings.
Company Size
51-200
Company Stage
Early VC
Total Funding
$116.5M
Headquarters
New York City, New York
Founded
2010
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?